Overall rank by patents
#47,643
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView Foreign Corporation
Innocoll Pharmaceuticals Limited
USPTO PatentsView assignee record - 5 granted patents across 5 technology areas, active 2019–2024. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: C07K (PEPTIDES).
5
Total patents granted
5
CPC technology areas
15.4
Avg claims per patent
+300%
5-year filing velocity
The verdict
Innocoll holds 5 US patents across 5 technology areas, rank #47,643 of 50,000 tracked assignees.
- #47,643
- of 50,000 US assignees by volume
- Top 56%
- by Innovation Score (33.3/100)
- 15.4
- avg claims per patent
- +300%
- filing velocity, last 5 yrs
Portfolio overview
Innocoll Pharmaceuticals Limited has been granted 5 US utility patents between 2019 and 2024, placing Innocoll Pharmaceuticals Limited at rank #47,643 across all assignees tracked by PlainPatent. This portfolio spans 5 distinct Cooperative Patent Classification (CPC) subclasses, averaging 15.4 claims per patent with primary concentration in C07K (PEPTIDES). As a Foreign Corporation, Innocoll Pharmaceuticals Limited is one of the more focused assignees in the PatentsView dataset. By volume, Innocoll sits between Inland PIPE Rehabilitation Llc (5 patents, rank #47,639) and Innon Holdings, Llc (5 patents, rank #47,647) - the closest US assignees by grant volume. The composite Innovation Score of 33.3/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 4 grants, compared with 1 in the 2015–2019 window, a +300% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Innocoll Pharmaceuticals Limited's 15.4 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 5 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Innocoll Pharmaceuticals Limited against peers pursuing similar technology classes.
Who files at Innocoll's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Inland PIPE Rehab…
INLAND PIPE REHABILITATION LLC
5 patents
- INLC Technology
INLC TECHNOLOGY CO., LTD.,
5 patents
- Inmate TEXT Servi…
INMATE TEXT SERVICE, LLC
5 patents
- Innereye
INNEREYE CO., LTD.
5 patents
- Innodem Neuroscie…
INNODEM NEUROSCIENCES
5 patents
- Innohome OY
INNOHOME OY
5 patents
- Innolith Assets
INNOLITH ASSETS AG
5 patents
- Innon Holdings
INNON Holdings, LLC
5 patents
- Innocoll Pharmace… ◀
INNOCOLL PHARMACEUTICALS LIMITED
5 patents
What this shows Innocoll holds 5 patents at rank #47,643, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Innocoll
By rank, the assignees closest to #47,643 in granted patent volume.
- Inland PIPE Rehabilitation Llc #47,639 · 5 patents
- INLC Technology Co., Ltd., #47,640 · 5 patents
- Inmate TEXT Service, Llc #47,641 · 5 patents
- Innereye Co., Ltd. #47,642 · 5 patents
- Innodem Neurosciences #47,644 · 5 patents
- Innohome OY #47,645 · 5 patents
- Innolith Assets Ag #47,646 · 5 patents
- Innon Holdings, Llc #47,647 · 5 patents
Leaders in C07K (Peptides)
Other assignees with the most granted patents in Innocoll's primary technology class.
- The Regents Of The University Of California 894 in class
- Regeneron Pharmaceuticals, Inc. 824 in class
- Immatics Biotechnologies Gmbh 678 in class
- Genentech, Inc. 565 in class
- The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 513 in class
- The Trustees Of The University Of Pennsylvania 501 in class
- Novartis Ag 407 in class
- The Board Of Trustees Of The Leland Stanford Junior University 400 in class
Innocoll's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
33 Top 56% higher than 44% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2019–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2019 | 1 | 20.0% |
| 2020 | 1 | 20.0% |
| 2023 | 2 | 40.0% |
| 2024 | 1 | 20.0% |
Which technologies does Innocoll Pharmaceuticals Limited patent most?
Top 5 of 5 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Focused
Claim Depth Standard
Velocity Accelerating
Frequently Asked Questions
How many patents does Innocoll Pharmaceuticals Limited hold?
Innocoll Pharmaceuticals Limited holds 5 US granted patents filed between 2019 and 2024, spanning 5 technology areas.
What is Innocoll Pharmaceuticals Limited's Innovation Score?
Innocoll Pharmaceuticals Limited has an Innovation Score of 33.3 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Innocoll Pharmaceuticals Limited focus on?
Innocoll Pharmaceuticals Limited's top technology area is C07K (PEPTIDES) with 3 patents. The company has filed patents in 5 CPC subclasses total.
Is Innocoll Pharmaceuticals Limited's patent filing rate increasing or decreasing?
Innocoll Pharmaceuticals Limited's recent filing velocity is +300% compared to the prior five-year period. This indicates accelerating innovation.
What does claim depth mean for Innocoll Pharmaceuticals Limited's patents?
Innocoll Pharmaceuticals Limited's patents average 15.4 claims each. This falls within the standard range, providing solid legal coverage.
How is the Innocoll Pharmaceuticals Limited patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
How to use this portfolio
Innocoll's 5 grants land it in the top 56% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Innocoll ranks #47,643 of 50,000. Top 50 holders
- Most of this portfolio concentrates in C07K - see who else leads that technology area. C07K leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.